Insitro, an AI-based pharma company, recently raised $143M summing up the venture capital to $243M. The firm will use this fund to hire experienced drug developers and also to fuel its liver-disease drug project. In 2019, it dealt with Gilead for this $1B project, gaining $15M upfront. Insitro focusses on neuroscience and hence uses human cells for neurological disease drug development. Also, it uses fresh training data to train its ML models.

Click here to read the full story